Estimating Costs of Market Exclusivity Extensions For 4 Top-Selling Prescription Drugs in the US
This study found that promoting timely generic availability and avoiding extending market exclusivity for top-selling drugs may result in substantial savings for US patients and payers, including both public and private health insurance programs.
Authors
- Dongzhe Hong (ORCID: https://orcid.org/0000-0002-6400-9667)
- S. Sean Tu (ORCID: https://orcid.org/0000-0003-0391-8186)
- Ameet Sarpatwari (ORCID: https://orcid.org/0000-0001-5043-6206)
- Aaron Seth Kesselheim (ORCID: https://orcid.org/0000-0002-8867-2666)
- Benjamin N. Rome (ORCID: https://orcid.org/0000-0001-5776-3293)
- Massimiliano Russo (ORCID: https://orcid.org/0000-0003-4953-9341)
- Reed F. Beall (ORCID: https://orcid.org/0000-0001-8188-7616)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of Calgary (CA)
- University of Alabama (US)
- The Ohio State University (US)
Publication Details
- Journal
- JAMA Health Forum
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1001/jamahealthforum.2025.2631
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00